title: Differences in efficacy of monepantel, derquantel and abamectin against multi-resistant nematodes of sheep.
abstract: Drug resistance has become a global phenomenon in gastrointestinal nematodes of sheep, particularly resistance to macrocyclic lactones. New anthelmintics are urgently needed for both the control of infections with multi-resistant nematodes in areas where classical anthelmintics are no longer effective, and the prevention of the spread of resistance in areas where the problem is not as severe. Recently, two new active ingredients became commercially available for the treatment of nematode infections in sheep, monepantel (Zolvix®) and derquantel, the latter used only in a formulated combination with the macrocyclic lactone, abamectin (Startect®). In order to assess the potential of the new actives for the control and prevention of spread of anthelmintic resistance, two characterized multi-resistant field isolates from Australia were used in a GLP (good laboratory practice) conducted efficacy study in sheep. Eight infected sheep in each group were treated orally according to the product labels with 2.5 mg/kg body weight monepantel, 0.2 mg/kg abamectin, or with the combination of 2.0 mg/kg derquantel and 0.2 mg/kg abamectin. The results demonstrate that monepantel was fully effective against multi-resistant species, Trichostrongylus colubriformis and Haemonchus contortus (99.9%). In contrast, the combination of derquantel and abamectin was effective against T. colubriformis (99.9%), but was not effective against larval stages of the barber's pole worm H. contortus (18.3%).
authors.affiliation: Novartis Centre de Recherche Santé Animale, CH-1566 St. Aubin, Switzerland. ronald.kaminsky@novartis.com
authors.forename: Ronald
authors.initials: R
authors.lastname: Kaminsky
authors.forename: Beatrice
authors.initials: B
authors.lastname: Bapst
authors.forename: Philip A
authors.initials: PA
authors.lastname: Stein
authors.forename: Guenther A
authors.initials: GA
authors.lastname: Strehlau
authors.forename: Brooke A
authors.initials: BA
authors.lastname: Allan
authors.forename: Barry C
authors.initials: BC
authors.lastname: Hosking
authors.forename: Peter F
authors.initials: PF
authors.lastname: Rolfe
authors.forename: Heinz
authors.initials: H
authors.lastname: Sager
mesh_terms: D000607:Aminoacetonitrile / Q000008:administration & dosage / Q000031:analogs & derivatives*; D000818:Animals; D000871:Anthelmintics / Q000008:administration & dosage*; D001315:Australia; D004351:Drug Resistance; D006189:Haemonchus / Q000187:drug effects / Q000302:isolation & purification; D007559:Ivermectin / Q000008:administration & dosage / Q000031:analogs & derivatives*; D007814:Larva / Q000187:drug effects; D009349:Nematode Infections / Q000188:drug therapy / Q000469:parasitology / Q000662:veterinary*; D012756:Sheep / Q000469:parasitology*; D012757:Sheep Diseases / Q000188:drug therapy* / Q000469:parasitology; D016896:Treatment Outcome; D014254:Trichostrongylus / Q000187:drug effects / Q000302:isolation & purification
chemical_list: D000871:Anthelmintics; D000607:Aminoacetonitrile; C048324:abamectin; D007559:Ivermectin; C533978:monepantel